The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).
- Muscular Diseases
- Myositis
- Lupus Erythematosus, Systemic
- Scleroderma, Systemic
- Scleroderma, Diffuse
- Autoimmune Diseases
- Sclerosis
Age: 18 years - 66+
Gender: All